Neuren Pharmaceuticals 대차 대조표 상태
재무 상태 기준 확인 6/6
Neuren Pharmaceuticals 의 총 주주 지분은 A$219.2M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$228.2M 및 A$9.0M 입니다. Neuren Pharmaceuticals 의 EBIT는 A$155.2M 이며 이자보상배율은 -14.3 입니다. A$213.2M 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
0%
부채 비율
AU$0
부채
| 이자 보상 비율 | -14.3x |
| 현금 | AU$213.17m |
| 주식 | AU$219.15m |
| 총 부채 | AU$9.00m |
| 총 자산 | AU$228.15m |
최근 재무 상태 업데이트
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04
재무 상태 분석
단기부채: NEU 의 단기 자산 ( A$228.0M )이 단기 부채( A$9.0M ).
장기 부채: NEU 의 단기 자산( A$228.0M )이 장기 부채( A$29.0K ).
부채 대 자본 내역 및 분석
부채 수준: NEU 부채가 없습니다.
부채 감소: NEU 지난 5년간 부채가 없습니다.
부채 범위: NEU 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.
이자 보장: NEU 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.